These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11459443)

  • 21. Intravesical chemotherapy.
    Prout GR
    Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
    [No Abstract]   [Full Text] [Related]  

  • 22. Poisson, Poisson-gamma and zero-inflated regression models of motor vehicle crashes: balancing statistical fit and theory.
    Lord D; Washington SP; Ivan JN
    Accid Anal Prev; 2005 Jan; 37(1):35-46. PubMed ID: 15607273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
    Prout GR; Kopp J
    Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644
    [No Abstract]   [Full Text] [Related]  

  • 24. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
    Holmäng S; Hedelin H; Anderström C; Johansson SL
    J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving removal-based estimates of abundance by sampling a population of spatially distinct subpopulations.
    Dorazio RM; Jelks HL; Jordan F
    Biometrics; 2005 Dec; 61(4):1093-101. PubMed ID: 16401283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
    Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
    [No Abstract]   [Full Text] [Related]  

  • 29. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors.
    Yan Y; Andriole GL; Humphrey PA; Kibel AS
    Cancer; 2002 Sep; 95(6):1239-46. PubMed ID: 12216091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical modelling for falls count data.
    Ullah S; Finch CF; Day L
    Accid Anal Prev; 2010 Mar; 42(2):384-92. PubMed ID: 20159058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of thiotepa in the treatment of superficial bladder tumors.
    Akdaş A; Kirkali Z; Sengör F; Ilker Y; Taşar C
    Turk J Pediatr; 1984; 26(1-4):243-50. PubMed ID: 6443167
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fluorescence diagnosis and photodynamic therapy in urology].
    Stepp H; Waidelich R
    Aktuelle Urol; 2007 Nov; 38(6):455-64. PubMed ID: 17987533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical methods for the analysis of relapse data in MS clinical trials.
    Wang YC; Meyerson L; Tang YQ; Qian N
    J Neurol Sci; 2009 Oct; 285(1-2):206-11. PubMed ID: 19709676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empirical receiver operating characteristic curve for two-sample comparison with cure fractions.
    Zhao X; Zhou X
    Lifetime Data Anal; 2010 Jul; 16(3):316-32. PubMed ID: 20221802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrete-time survival models with long-term survivors.
    Zhao X; Zhou X
    Stat Med; 2008 Apr; 27(8):1261-81. PubMed ID: 17676708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The analysis of count data: a gentle introduction to poisson regression and its alternatives.
    Coxe S; West SG; Aiken LS
    J Pers Assess; 2009 Mar; 91(2):121-36. PubMed ID: 19205933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA
    Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
    [No Abstract]   [Full Text] [Related]  

  • 38. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
    Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R
    Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of recurrence in non-invasive bladder carcinoma. Experiences with 400 patients].
    Burk K; Troller RM; Pittner P
    Urologe A; 1983 Sep; 22 Suppl():332-6. PubMed ID: 6356556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FISH test for the diagnosis, surveillance, and prognosis of transitional cell carcinoma of the bladder.
    Haddad FS
    J Med Liban; 2008; 56(4):230-2. PubMed ID: 19115598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.